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Background: The purpose of the study was to evaluate the effects of krill oil (KO) on cognition and depression-like
behaviour in rats.
Methods: Cognition was assessed using the Aversive Light Stimulus Avoidance Test (ALSAT). The Unavoidable
Aversive Light Stimulus (UALST) and the Forced Swimming Test (FST) were used to evaluate the antidepressant-like
effects of KO. Imipramine (IMIP) was used as the antidepressant reference substance.
Results: After 7 weeks of KO intake, both males and females treated with KO were significantly better in
discriminating between the active and the inactive levers in the ALSAT from day 1 of training (p<0.01). Both KO
and IMIP prevented resignation/depression on the third day in the UALST. Similarly, a shorter immobility time was
observed for the KO and IMIP groups compared to the control in the FST (p<0.001). These data support a robust
antidepressant-like potential and beneficial cognitive effect of KO. Changes in expression of synaptic
plasticity-related genes in the prefrontal cortex and hippocampus were also investigated. mRNA for brain-derived
neurotrophic factor (Bdnf) was specifically upregulated in the hippocampus of female rats receiving 7 weeks of KO
supplementation (p=0.04) and a similar trend was observed in males (p=0.08). Males also exhibited an increase in
prefrontal cortex expression of Arc mRNA, a key protein in long-term synaptic plasticity (p=0.05). IMIP induced clear
effects on several plasticity related genes including Bdnf and Arc.
Conclusions: These results indicate that active components (eicosapentaenoic acid, docosahexaenoic acid and
astaxanthin) in KO facilitate learning processes and provide antidepressant-like effects. Our findings also suggest
that KO might work through different physiological mechanisms than IMIP.
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Dietary intake of n-3 polyunsaturated fatty acids
(PUFAs) is known to be beneficial for general health [1].
It is well documented that supplementation of the bio-
active n-3 PUFAs, eicosapentaenoic acid (EPA) and do-
cosahexaenoic acid (DHA), positively influence the
cardiovascular system [2] and show anti-inflammatory
effects [3,4]. The brain contains up to 60% lipids and a
large portion of these are PUFAs, the most abundant* Correspondence: lena.burri@akerbiomarine.com
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reproduction in any medium, provided the orbeing DHA [5]. Clinical data and animal experiments
have establish that n-3 PUFAs are involved in maintain-
ing a healthy brain and enhancing brain functions such
as memory and learning [6,7], reactivity, attention, cog-
nitive performance, and mood [8]. The hippocampal for-
mation is a brain region critical for learning and memory
[9]. Major depression is associated with neuronal atrophy
in the hippocampus and hippocampal volume is reduced
in patients with depression [10,11].
Several epidemiological studies suggest that depression
is associated with lower n-3 PUFA levels and that n-3
PUFA treatment can be used in the treatment andl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[12] and in children [13]. Recent animal studies have
shown that dietary supplementation of n-3 PUFAs can
reduce immobility in the Forced Swimming Test (FST),
a test used for validating depression status, while
deprivation of n-3 PUFA can promote aggression and
depression [14-18]. One hypothesis is that n-3 PUFAs
exert their effect on the nervous system by regulating
cyclic AMP (cAMP), cAMP response element binding
protein (CREB), and the expression of downstream tar-
get genes such as brain-derived neurotrophic factor
(BDNF) [17,18]. This is in line with studies showing
that expression of BDNF and activation of the BDNF
receptor, is reduced in the hippocampus and neocor-
tex of rodents subjected to behavioural stress but en-
hanced following treatment with antidepressant drugs
[19-25].
Antarctic krill, Euphausia superba, is a shrimp-like
zooplankton and constitutes one of the largest biomasses
of an individual species. Both fish oil (FO) and krill oil
(KO) contain high levels of the essential polyunsaturated
lipids EPA and DHA, but bond in different structural
forms. In FO, EPA and DHA are found in the form of
triglycerides, whereas in KO they are mainly in the form
of phospholipids [26]. In addition to high levels of phos-
pholipids, KO contains the natural antioxidant astax-
anthin, that protects the unsaturated bonds from
oxidation [27], shows antianxiety-like effects [28], and
impacts on memory improvement in a common labora-
tory mouse model (BALB/c mice) [29]. The high content
of phospholipids makes krill-derived products such as
KO and krill powder interesting as a source of n-3
PUFAs. As the different structure of krill fatty acids may
affect their incorporation into neuronal cell membranes,
krill products may be particularly effective in modulating
neuronal membrane function and signalling, including
processes of synaptic transmission and plasticity. At
present there is only one animal study addressing the
effect of krill-derived phospholipids on brain function
in rats [30]. The authors observed that spatial lear-
ning ability (for the radial arm maze task) and cell
generation in the dentate gyrus was enhanced after
KO administration. Here, we studied the effect of KO
on cognition (learning acquisition and working mem-
ory) and depression, and examined a possible modula-
tion of genes linked to synaptic plasticity, memory
and adaptive brain function.
Results
After 6 weeks of treatment administration, the cognitive
and antidepressant effects of KO in male and female rats
were monitored with two different models, the Condi-
tioned Light Extinction Test (ALSAT and UALST proce-
dures) and FST.Cognition and depression-like behaviour in the
Conditioned Light Extinction Test (CLET)
Cognition: The cognitive effects of KO were assessed using
the Aversive Light Stimulus Avoidance Test (ALSAT)
procedure of the CLET
The rats were continuously exposed to the bright lit
chamber unless an active bar-press occurred. The num-
ber of presses on the levers and the lever discrimination
were measured during two 20 min learning acquisition
sessions (Days 43 and 44) and in a third session (Day
45), when the active lever was inactivated. Total number
of presses is a measurement of activity and alertness of
the animals and a reduction in lever presses can be a
sign of sedation. KO intake did not have any effect on
the total number of presses (sum of active and inactive
lever presses), whereas the antidepressant IMIP gave a
significant reduction in total number of lever presses.
The results from training day one (Day 43) are shown in
Figure 1a and b.
The IMIP group had again less presses than the con-
trol group and the KO group did not change from the
control (the total number of presses for all two days and
both genders is presented in Additional file 1: Table S1).
Although the total number of presses was similar in
the control and KO groups, a clear difference in the abi-
lity to discriminate between the active and inactive lever
(assessment of cognitive abilities, i.e. learning and work-
ing memory) was observed. Male and female rats recei-
ving KO discriminated between the active lever and the
inactive one during the whole two test sessions based on
higher lever presses on the active lever during the light
period and the discrimination was observed from the 1st
day of training (Figure 2 and Additional file 1: Tables S2
and S3).
In addition, male rats administered IMIP showed a
tendency for discrimination between the levers at day 2
and a significant successful discrimination was observed
for female rats in day 1 and 2 (Additional file 1: Table
S3). Day 1 is shown in Figure 2b).
Depression: the antidepressant-like effects of KO were
evaluated in the Unavoidable Aversive Light Stimulus Test
procedure (UALST) in the CLET
On day 3 (Day 45) the active lever was deactivated and
the number of presses was recorded. A decrease in the
number of presses on both levers and particularly on the
active lever, when it was deactivated on day 3 compared
to when it was active on day 2 can be interpreted as a
sign of resignation or depression-like state, and as de-
motivation due to the absence of positive reinforcement
in the form of 30 s periods of darkness (Additional file
1: Table S4).
The total number of active lever presses (TALP) sig-
nificantly decreased in control rats, while KO and IMIP
Figure 1 The effect of KO and IMIP on total lever presses on
day 1 in the Conditioned Light Extinction Test. (a) Male rats and
(b) Female rats. ** p<0.01 (vs. control). The box plots show the 10th,
25th 50th (median), 75th and 90th percentiles).
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Table S4).
In addition, despite the absence of positive reinforcement,
the KO groups of both genders continued to discriminate
correctly between the two levers.
The effect of KO in the Forced Swimming Test (FST)
One way of measuring the state of depression in labora-
tory animals (rodents) is the FST. The immobility time
(passive floating in water) is a measure of depression-
like behaviour (learned helplessness) that can be modu-
lated by antidepressant agents. After 7 weeks of treatment
there was no difference in the immobility time betweenthe three treatment groups when they were subjected
to a pre-test session of the FST (Figure 4a and b and
Additional file 1: Table S5: males: Hdf(2)=0.53; p=0.77;
females: Hdf(2)=3.24; p=0.20). During the test session,
significant differences were observed among immobility
times in the male as in the female groups (Hdf(2)=18.86;
p=0.0001 and Hdf(2)=22.44; p=0.0001, respectively).
Decrease in the duration of immobility in groups receiving
KO or IMIP compared to the control group were
observed (males: KO: U=16.5; p=0.0005 and IMIP:
U=2.50; p=0.0001; females: KO: U=4, p=0.0001 and IMIP:
U=1; p=0.0004) (Figure 4c and d). When the immobility
time was compared between the pre-test and the test ses-
sion, control rats showed an increase in immobility (con-
trol: males: z=2.98, p=0.003 and females: z=3.06, p=0.002),
while a decrease was observed for the KO (males: z=2.04,
p=0.04 and females: z=2.92, p=0.004) and IMIP groups
(males: z=2.70, p=0.007 and females: z=2.20, p=0.03)
(Additional file 1: Table S6).
The effect of KO on gene expression
Quantitative real-time PCR was used to determine gene
expression changes of Bdnf associated plasticity regulated
genes in the prefrontal cortex and the dentate gyrus of the
hippocampus. In the dentate gyrus (Figure 5a and b), the
level of total Bdnf mRNA (primers targeting the common
coding region, exon IX) was significantly up-regulated in
females (p=0.04) by KO and a strong tendency towards
up-regulation was observed in the male group (p=0.08)
compared to their respective control groups. IMIP treat-
ment resulted in an up-regulation in the dentate gyrus of
both male and female rats of several plasticity-associated
genes including total Bdnf (male p=0.004; female
p=0.004), the activity-regulated Bdnf exon IV (male
p=0.001; female p=0.03), and the activity-regulated cyto-
skeleton-associated protein (Arc) (male p=0.03; female
p=0.04) (Figure 5a and b). In addition, male IMIP-treated
rats exhibited significantly enhanced expression of Neuri-
tin (p=0.02) and a tendency for increased expression of
Narp and Tieg1 (p=0.06) relative to control. In the pre-
frontal cortex (Figure 6a and b), Arc mRNA levels
(p=0.05) were increased after KO administration in male,
but not female rats. A trend towards increased expression
of Bdnf exon VI was also observed in male, KO-treated
rats. Increases in total Bdnf (p=0.01), Bdnf exon IV
(p=0.0002), Narp (p=0.05) and Neuritin (p=0.015) was
found in the prefrontal cortex of males receiving IMIP
compared to the control group. None of the analyzed
mRNAs differed significantly in females between KO and
the control group.
Discussion
The aim of this study was to evaluate the impact of oral
administration of KO on depression, cognitive function
Figure 2 The effect of KO and IMIP on active (ALP) and inactive (ILP) lever presses on day 1 in the Conditioned Light Extinction Test.
(a) Male rats. (b) Female rats. * p<0.05; ** p<0.01 (ALP vs. ILP). The box plots show the 10th, 25th 50th (median), 75th and 90th percentiles).
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in neuronal connectivity. The KO dose given to study
rats is relevant for human consumption as the EPA and
DHA amount given (1.25% KO of diet) corresponds to a
human daily intake of 0.8 g EPA and DHA in an 8.4 MJ/
day diet. A separate group that received the tricyclic
antidepressant IMIP as a comparative positive control
was included. The results showed that 7 weeks of KO
supplementation significantly improved learning and
working memory in the ALSAT and displayed significant
antidepressant-like effects in the UALST and FST. In
addition, KO enhanced expression of Bdnf mRNA,
which is a gene implicated in neuronal growth and
differentiation.Cognition and depression in the Conditioned Light
Extinction Test (CLET)
In general the same effects were seen in both genders
with the exceptions pointed out. The CLET is an etho-
logical model used to score learning ability using the
ALSAT procedure [31,32] and antidepressant-like effects
using the UALST in rat [33].
The administration of KO did not result in any sign
of sedation (similar number of total lever presses as
in control group), a common problem with classic
antidepressants and also seen in this study with IMIP.
IMIP was previously shown to have a sedative effect
on motor activity in rats [34]. KO administration
increased the ability of the rats to discriminate
Figure 3 The effect of KO and IMIP on resignation/depression in the Conditioned Light Extinction Test. The total active lever presses on
day 2 (TALP D2) vs. total active lever presses on day 3 (TALP D3). (a) Male rats (b) Female rats. * p<0.05 (TALP D2 vs. TALP D3). The box plots
show the 10th, 25th 50th (median), 75th and 90th percentiles).
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be interpreted as a sign of improved learning and
memory function. A significantly higher number of
presses were placed on the active rewarding lever
compared to both control and IMIP receiving rats.
Whereas the control group showed signs of resigna-
tion when the active lever was made inactive on test
day 3, both IMIP and KO contributed to an antidepres-
sant-like effect and no reduction in the number of lever
presses between day 2 and day 3 was observed despite the
absence of positive reinforcement.
Wistar Unilever rats are very sensitive to resignation/
depression [35]. That is why these rats were chosen in
this study to assess the antidepressant-like effects of KO,the primary objective of the study. With other laboratory
rat strains, i.e. Wistar Han or Sprague–Dawley, generally
rats learn to discriminate the active lever from the in-
active one at the end of the first test session. In our
study, after two-day training in the CLET, the KO and
IMIP groups showed a higher number of active relative
to inactive lever presses. However, the KO group dis-
played more active lever presses as early as day 1, at a
time when the results with the control and IMIP groups
did not show any discrimination. Although based on a
single experiment, these results indicate that KO may
accelerate learning processes. The light environment
represents a stress for rats and is a disruptive factor in
the acquisition of operant conditioning. Astaxanthin has
Figure 4 Effects of KO and IMIP on immobility in the Forced Swimming Test. The effect on immobility during the pre-test session in (a)
Male rats and in (b) Female rats. The effect on immobility during the test session in (c) Male rats and in (d) Female rats. *** p<0.001 (vs. control).
The box plots show the 10th, 25th 50th (median), 75th and 90th percentiles).
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nitive functions such as reaction time, attention and
working memory [29,36]. The exact role of the astax-
anthin in KO remains to be determined and if the rather
low amounts given to KO-treated rats help to exploit
without stress the environmental parameters of the
learning situation in the CLET and to display better cog-
nitive performances remains to be proven.
During the UALST session, when the active lever is
deactivated, only KO rats displayed lever pressing acti-
vity relatively high compared with that of control and
IMIP rats. Thus, KO rats did not resign themselves to
suffer passively the unavoidable aversive light stimulus
by continuing to press more on the levers and to dis-
criminate the active lever from the inactive one. This
effect could be mainly due to the n-3 PUFAs, astax-
anthin having no known effect on depression [28].Depression in the FST
The antidepressant-like effect of KO was further studied
using the FST. Dietary supplementation of KO resulted
in reduced immobility time in water. This is consistent
with studies demonstrating that alpha-linolenic acid
(ALA) administration (ranging from 30 days to 15 weeks)
and EPA and DHA administration (12 weeks) reduced
immobility and climbing in the FST [14-18]. It is known
that short-term administration of PUFAs fail to induce
the antidepressant effects in FST [14,37].
Improved reference and spatial memory was recently
reported in the radial maze test for rats that had
received a diet supplemented with isolated phospholipids
from KO [30]. Moreover, in these rats, DHA levels were
shown to be significantly increased in the cerebral cor-
tex, as well as in the hippocampus [30]. The KO used in
the present study was previously shown to similarly
Figure 5 Seven weeks of KO administration induces brain-derived neurotrophic factor (Bndf) mRNA expression in the hippocampus.
Changes in mRNA expression following KO administration is expressed as fold change relative to the control group. (a) Male rats n=12 control,
n=12 IMIP, n=11-12 KO, (b) Female rats n=10-12 control, n=7-9 IMIP, n=13-14 KO. * p<0.05 from Student`s t-test.
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study was in comparison to FO, which did not lead to
an increase in brain DHA levels. Underlying reasons
explaining the difference between KO and FO adminis-
tration might be related to different molecular forms of
EPA and DHA (phospholipids versus triglycerides),
which has recently been reviewed in more detail [39].
Taken together, these studies indicate that KO, which is
rich in n-3 containing phospholipids, can increase DHA
levels in the brain and may protect from depression-like
behaviour, as measured by the UALST and FST. In
addition, the study suggests that KO can improve learning
acquisition and working memory as evaluated in the
ALSAT.
Very recently, it was shown that dietary supplementa-
tion of KO attenuates inflammation and oxidative stress
in ulcerative colitis in rats [40]. Especially, the role of in-
flammatory processes on emotion is indicated by find-
ings of a link between depression and elevated systemic
inflammatory markers [41]. It was demonstrated that
antidepressant agents are able to prevent or suppress in-
flammation and depressive symptoms [42,43] induced by
systemic injection of cytokines [44,45]. C-reactive protein
(CRP), as a biomarker of inflammation [46], is involved instroke and cognitive impairments [47], and KO phospholi-
pids demonstrated anti-inflammatory responses, lowering
CRP levels in human subjects [48,49]. Thus, KO might be
used to influence mood and cognition in subjects with an
inflammatory condition.
Gene expression
Up-regulation of BDNF signalling and downstream gene
expression is implicated in the action of several well-
known antidepressant drugs [19,23,50]. N-3 PUFAs have
also been shown to modulate BDNF expression and sig-
naling in a brain region- and treatment-specific manner
[18,51,52].
The present study shows that long-term KO adminis-
tration to rats results in gender and brain region-specific
changes in mRNA expression. Recent data also suggests
that n-3 PUFAs can induce antidepressant effects
associated with increased serotonergic neurotransmis-
sion and neurotrophin expression in the hippocampus
[18,51,53].
Abnormalities in the PUFA content in the brain might
affect mood control through effects on neurotrophin
expression and signalling and deficiencies have been
shown to reduce neurotrophin levels in the prefrontal
Figure 6 Seven weeks of KO administration leads to gender-specific effects on activity-regulated cytoskeleton-associated (Arc) mRNA
regulation in the prefrontal cortex. Changes in mRNA expression following KO administration is expressed as fold change relative to the
control group. (a) Male rats n=12 control, n=11-12 IMIP, n=12 KO, (b) Female rats n=11-12 control, n=8-9 IMIP, n = 14 KO. * p<0.05 from
Student`s t-test.
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15 weeks of ALA deprivation results in significantly
decreased levels of BDNF expression, CREB transcrip-
tion factor activity, and p38 mitogen-activated protein
kinase (MAPK) activity in the frontal cortex [55].
Although IMIP and KO treatments both have
antidepressant-like behavioural effects, these treatments
do not have identical effects on gene expression. IMIP
and KO both induce Bdnf, but only IMIP enhanced the
expression of genes previously associated with BDNF
signaling and long-term synaptic plasticity [19,56].
Hence, the antidepressant-like effects of IMIP and KO
are correlated with distinct neurobiological mechanisms
at the level of gene expression. However, it remains pos-
sible that KO regulates BDNF-responsive target genes
on a different time course than does IMIP. The observed
increase of Bdnf mRNA level observed in the present
study might be a result of increased transcription or an
effect on RNA turnover. Another study with n-3 PUFA
supplementation (0.5% EPA and 1% DHA for 12 weeks)
showed antidepressant effects, a change in CREB protein
levels, but no increase in hippocampal BDNF protein
levels [17]. This might be explained by differences intypes, forms and amounts of n-3 PUFAs, and the fact
that real-time PCR is a more sensitive method then
Western blot. On the other hand, inclusion of 1.2%
DHA in the diet was able to increase BDNF protein
levels in rat hippocampal tissue after brain trauma [52].
Arc has key regulatory roles in protein synthesis-
dependent synaptic plasticity, memory formation, and
postnatal cortical development [57,58]. Interestingly, KO
treatment induced Arc in the male prefrontal cortex,
although Bdnf levels were not altered. On the other
hand IMIP induced the expression of Bdnf and several
BDNF-regulated genes, but did not increase Arc expres-
sion under these conditions. Another possible mechan-
ism of Arc induction is through activation of muscarinic
cholinergic receptors (mAchR). It has previously been
shown in vitro and in vivo that activation of mAchR
induces Arc expression [59-61].
In KO, the major phospholipid species is phosphatidyl-
choline, which may provide a source for acetylcholine
biosynthesis [62]. Learning ability has previously been
associated with increased cerebral levels of acetylcholine
after the intake of a DHA supplemented diet in a rat
model and different sources of DHA intake increase the
Table 1 Diet composition (g/100 g of diet)
Control IMIP KO
Protein 16.40 16.40 16.37
Fat 4.00 4.00 4.20
Carbohydrate 48.50 48.50 48.40
Fatty acids
Palmitic acid 0.50 0.50 0.69
Stearic acid 0.10 0.10 0.11
Oleic acid 0.70 0.70 0.87
Linoleic acid 2.00 2.00 2.02
Linolenic acid 0.10 0.10 0.10
EPA 0.00 0.00 0.15
DHA 0.00 0.00 0.07
IMIP Imipramine, KO krill oil.
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Future studies need to investigate possible changes in
acetylcholine levels after KO administration.
Conclusions
IMIP and KO both enhance cognition and provide
antidepressant-like effects. IMIP and KO treatments are
associated with enhanced Bdnf mRNA expression but
have distinct effects on the expression of Arc and other
synaptic-plasticity associated genes, suggesting partially
distinct neurobiological mechanisms. Subject to the con-
firmation of these results in clinical trials, KO, with the
synergy of its various components such as n-3 phospho-
lipids and astaxanthin, might play a role in depression
and cognition, and thus offer a novel approach to allevi-
ate neurological and psychiatric disorders.
Methods
Animals and diet
The animal experiments have been carried out in the
laboratories of ETAP-Applied Ethology (Vandoeuvre-
lès-Nancy, France). The experiments were performed in
accordance to the guidelines provided by the ASAB Eth-
ical Committee for the use of animals in behavioural
research (Animal Behavior 2006; 71:245–53) and by the
Canadian Council on Animal Care. All experimental
procedures were carried out according to French regula-
tions (decree no. 87–848) and in compliance with the
European Economic Community Directives (86/609/CEE
and 2010/63/EU) on animal welfare. In total 38 male
and 38 female adult Wistar-Unilever rats (Harlan
Laboratories, The Netherlands), with starting weights of
175-200 g (males) and 125-150 g (females) have been
used in this study. The six-week old male and female
rats were maintained in two separate facilities and
housed two per cage in a regulated environment
(temperature 22±2°C; humidity 50±10%; 12 h inverted
light–dark cycle). The rats were allowed free access to
food and tap water. After 7 days of acclimatization the
rats were randomly divided into three different treat-
ment groups. KO, (Aker Biomarine Antarctic AS,
Norway), was daily administered by oral gavage at a dose
corresponding to 1.25% of the daily ration of food for
7 weeks. The average dose of KO given was 0.2 g/rat/
day. As a positive reference substance the tricyclic anti-
depressant Imipramine (IMIP) (Sigma-Aldrich, France)
was given to a separate treatment group, and the control
animals received water by oral gavage. Each day, KO was
mixed with natural spring water (Cristaline, France) at
the concentration of 33% (v/v) and stirred until
homogenization just before its oral administration. The
diet compositions are reported in Table 1.
The volume of administration (VA) was calculated for
each rat according to its group treatment and the meanweight of food consumed the 2 or 3 previous days as
follow:
VA = (DoseKO*Weightfi/DensityKO)*3
VA: volume of administration
DoseKO: dose of treatment (0.0125)
Weightfi: mean weight of food intake consumed the 2
or 3 previous days
DensityKO: density of KO (0.979)
Imipramine was daily prepared fresh before its admi-
nistration for 7 weeks. It was dissolved in water and then
stirred until homogenization just before its oral adminis-
tration at the daily dose of 20 mg/kg body weight, for
6 weeks before testing and 1 week during the testing
period. The volume of administration was 7.5 ml/kg.
The experimental set up is shown in Figure 7.
Because it is necessary to administer exact doses of
the studied products by gavage, gastric feeding needles
with a ball tip were used by experienced researcher.
These needles were used to prevent introduction of the
needle into the trachea and to prevent trauma to the
oral cavity and to the esophagus. Feeding needles, fitted
to a syringe, are carefully inserted through the mouth
into the lower esophagus in hand restraint rats. Gene-
rally, introduction of the needle toward the rear of the
mouth induces swallowing and the needle readily enters
the esophagus to deliver the syringe content without in-
ducing the stress associated with oral administration
during the following treatments.
Conditioned Light Extinction Test (CLET)
Cognition: the Aversive Light Stimulus Avoidance Test
(ALSAT) procedure
The CLET apparatus (TESLAW, ETAP, France) consists
of a chamber (50×40×37 cm) with a light level main-
tained at 1200 lux and allows the rats to escape from an
aversive light stimulus by turning off the light. Two
levers are included: an active one causing a 30-s period
Figure 7 The timing of test substance (KO, IMIP, or control) administration and behavioural studies. The Conditioned Light Extinction
Test (ALSAT: cognition, and UALST: depression) was performed on Days 43, 44 and 45 (corresponds to Day 1, 2 and 3), whereas the Forced
Swimming Test (FST) was performed on Days 46 and 47. Animals were sacrificed at Day 50.
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down and an inactive one, which was not reinforced
[31,32,64]. After 6 weeks of treatment administration, on
the first and second day (Days 43 and 44) of the 7th
week, each rat was continuously exposed to the brightly
lit chamber during a 20 min learning acquisition session,
unless an active barpress occurred (assessment of cogni-
tive abilities, i.e. learning and working memory).
The total number of active and inactive lever presses
was automatically recorded in both light and dark peri-
ods during the first and second test sessions (Days 43
and 44) and in light during the third session (Day 45).
The lever pressing activity was studied through the total
number of presses on both levers and the discrimination
by comparing the active lever presses with the filtered
inactive ones during the light period. Since each time
the rat pressed the active lever a 30s period of darkness
was induced, it was necessary to filter the inactive lever
presses during the light period to be able to discriminate
between the two levers during the two test sessions of
learning. Thus, after pressing the inactive lever during
the light period, the presses performed on this lever du-
ring the following 30s were not taken into account in
assessing the discrimination between the levers.
Depression: Unavoidable Aversive Light Stimulus Test
(UALST)
Following the learning sessions on days 43 and 44, on
the third day (Day 45), the active lever was deactivated
and the two levers were inactive during the 20 min-test
session and thus the aversive light stimulus could not be
avoided (assessment of the resignation behaviour i.e.,
depression-like state).
Resignation was measured by assessing the change of
total lever presses on both levers and particularly on the
active lever (total active lever presses: TALP) between
the second session of learning acquisition (Day 44) and
the third session (Day 45), where the active lever
was deactivated and therefore where no positive rein-
forcement in the form of periods of darkness could be
obtained. In this situation, extinction of the pressing be-
haviour is rapidly observed in untreated rats, while ratstreated with antidepressant have been shown to continue
to press on the levers [33]. Resignation or de-motivation
can only be measured in a context in which positive
reinforcement was experienced (active lever pressing).
Therefore, only animals that were active in the first
phase of the procedure (i.e. that pressed at least once
each lever on Day 2) were included in the depression
study.
Forced Swimming Test (FST)
The FST apparatus (ETAP, France) consisted of a Plexi-
glas cylinder (50x20 cm i.d.) filled with water at 25°C to
a depth of 30 cm. On day 46 (FST pre-test session), each
rat was individually placed into the cylinder for 15 min.
The water was changed after every trial to eliminate
urine, faeces, and odor clues left from the previous rat.
After the swimming session, the rat was removed from
the cylinder, dried with towels, and then received its
respective treatment. Then it was placed under a red
light (30°C) for 20 min before returning it to its home
cage. Twenty-four hours later (Day 47), the rat was once
again individually subjected to the same swimming test
for 5 min (FST test session). According to Porsolt’s pro-
cedure [65,66], with some modifications [35,67], in
addition to the daily treatment of the previous weeks,
between pre-test and test sessions, the treatments were
administered orally three times as follows: immediately
after the pre-test, as well as 5 h and 1 h before the test.
Immobility, considered as the marker for depression,
was defined as absence of movement, with the body
inclined forward, passively floating, with immobile paws,
as determined by video recordings.
The test was performed and immobility time scored
by experimenters unaware of the administered products.
The nature of the products was disclosed by the scien-
tific director only after the end of the statistical data
processing.
Statistical analysis of behaviour data
The Kruskal-Wallis test (KWT) was used to compare
the different treatment groups. When a significant diffe-
rence was observed, the Mann-Whitney U-test (MWT)
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group. For the repeated measures, the Wilcoxon test
(WT) was used for each variable in each treatment
group. The results are expressed as median with inter-
quartile range values. Differences were considered to be
significant at the level of P<0.05. All statistical analyses
were carried out using the StatViewW5 statistical package
(SAS, Institute, Inc., USA).
Biological sampling
On day 50, animals were anaesthetized with sodium
pentobarbital (Ceva Santé Animale, Libourne, France)
injected intraperitoneally at the dose of 100 mg/kg. Each
rat was then euthanized by decapitation and trunk
blood was collected in 2 EDTA tubes (Terumo, Leuven,
Belgium) and immediately centrifuged (2200 g; 5 min;
4°C). Plasma was collected and aliquoted into 2×2 ml po-
lypropylene tubes (Eppendorf, Le Pecq, France) and stored
at −80°C for future use. Brains were removed from skulls
immediately after decapitation and were cooled down dur-
ing 1 min in a phosphate buffered solution (0.1 M; pH 7.4;
ref: P7994; Sigma, St-Quentin Fallavier, France) at 4°C.
Each brain was subsequently divided into 3 parts by realis-
ing 2 cuts in the coronal plane with a rat brain slicer
matrix: a first cut was made at the level of the optic
chiasm, and a second one between the cerebellum and
cerebral hemispheres. The sections were then submerged
in 15 ml of RNAlaterW reagent solution (Applied Biosys-
tems, Courtaboeuf, France). After storage at 4°C over-
night, samples were stored at −80°C until dissection and
RNA purification.
RNA isolation, cDNA synthesis and qPCR
Brains were maintained at −80°C until dissection. Dis-
sections were carried out under RNAse free conditions.
The pre-frontal cortex and hippocampal dentate gyrus
were dissected and stored in RNAlaterW until RNA puri-
fication. Total RNA was purified with mirVana™ miRNA
Isolation Kit (Ambion, Life technologies, Paisley, UK)
according to the manufactures protocol. The tissues
were homogenized in 600 μl ice cold lysis buffer
provided with the mirVana kit, using the Prelyse sys-
tem (Prelyse™ 24, Bertin Technologies, Montigny-le-
Bretonneux, France) and recommended ceramic beads
(03961ck14). The RNA was eluted in 100 μl 10 mM
Tris–HCl and DNAse (Turbo DNAse Kit, Ambion) trea-
ted before cDNA synthesis. 300 ng of total RNA was
used for cDNA synthesis using the iScript™ cDNA Syn-
thesis Kit (BioRad, Hercules, CA, USA). The cDNA was
diluted 10 times in RNAse and DNAse free water and
analyzed with real time PCR on a Roche LightCycler
480. 10 μl reactions were run in 384-well plates using
gene specific primers (Additional file 1: Table S7) and 2x
PerfecCTa™ SYBRW Green FastMix™ (Quanta BioScience,Inc., Gaithersburg, MD) at 60°C. A pooled sample of all
cDNAs was used to generate standard curves for all genes
analyzed. The standard curves were used for relative
quantification of the individual samples.
NormFinder was used to check the stability of three
different normalization genes [68]. In both the male and
the female groups cyclophilin was clearly more stable
than the other two and chosen for normalization. The
GraphPad Software was used to remove outliers.
Additional file
Additional file 1: Table S1. Effects of KO and IMIP on total lever
presses on day 1, 2 in the ALSAT and day 3 in the UALST in male and
female rats (Median with interquartile range values). Table S2. Effects of
KO and IMIP on lever discrimination on days 1, 2 in the ALSAT, and day 3
in the UALST, in male rats (Median with interquartile range values). Table
S3. Effects of KO and IMIP on lever discrimination on days 1, 2 in the
ALSAT, and day 3 in the UALST, in female rats (Median with interquartile
range values). Table S4. Effects of KO and IMIP on resignation/depression
on day 3 in the UALST in male and female rats (Median with interquartile
range values). Table S5. Effects of KO and IMIP on immobility during the
pre-test session in the FST in male and female rats (Median with
interquartile range values). Table S6. Effects of KO and IMIP on change in
immobility time between the pre-test and test sessions in the Forced
Swimming Test (Median with interquartile range values). Table S7.
Primer sequences and accession numbers for analyzed genes.
Abbreviations
ALA: Alpha-linolenic acid; ALSAT: Aversive light stimulus test; ARC: Activity-
regulated cytoskeleton-associated protein; BDNF: Brain-derived neurotrophic
factor; cAMP: Cyclic adenosine monophosphate; CLET: Conditioned light
extinction test; CREB: cAMP response element binding protein; CRP: C-
reactive protein; DHA: Docosahexaenoic acid; EPA: Eicosapentaenoic acid;
FST: Forced swimming test; FO: Fish oil; IMIP: Imipramine; KO: Krill oil;
MAPK: Mitogen-activated protein kinase; KWT: Kruskal-Wallis test;
MWT: Mann–Whitney U-test; PCR: Polymerase chain reaction;
PUFA: Polyunsaturated fatty acids; TALP: Total number of active lever presses;
TrkB: Tropomyosin receptor kinase B; UALST: Unavoidable aversive light
stimulus test; WT: Wilcoxon test.
Competing interests
The authors have read the journal's policy and have the following conflicts:
Lena Burri and Kjetil Berge are employed in Aker BioMarine ASA, which
partly paid for the study.
Authors’ contributions
AD and MM have been in charge of the behavioural experiments. KW, DP
and CB have been responsible for the planning and carrying out the gene
expression analysis. LB and KB have designed the study. All authors have
been contributing to the interpretation of the data and the writing of the
manuscript. All authors read and approved the final manuscript.
Acknowledgement
This research was supported by Aker BioMarine ASA and by Norwegian
Research Council grant 199360.
Author details
1Department of Biomedicine and KG Jebsen Centre for Research on
Neuropsychiatric Disorders, University of Bergen, Jonas Lies vei 91, Bergen
NO-5009, Norway. 2Aker Biomarine ASA, Fjordalleen 16, Oslo NO-0115,
Norway. 3ETAP-Applied Ethology Department of Neuropsychopharmacology,
13 rue Bois de la Champelle, Vandoeuvre-lès-Nancy 54500, France.
Received: 27 November 2012 Accepted: 19 January 2013
Published: 25 January 2013
Wibrand et al. Lipids in Health and Disease 2013, 12:6 Page 12 of 13
http://www.lipidworld.com/content/12/1/6References
1. Siriwardhana N, Kalupahana NS, Moustaid-Moussa N: Health benefits of n-3
polyunsaturated fatty acids: eicosapentaenoic acid and docosahexaenoic
acid. Adv Food Nutr Res 2012, 65:211–222.
2. Delgado-Lista J, Perez-Martinez P, Lopez-Miranda J, Perez-Jimenez F: Long
chain omega-3 fatty acids and cardiovascular disease: a systematic
review. Br J Nutr 2012, 107(Suppl 2):S201–S213.
3. Miles EA, Calder PC: Influence of marine n-3 polyunsaturated fatty
acids on immune function and a systematic review of their effects
on clinical outcomes in rheumatoid arthritis. Br J Nutr 2012, 107
(Suppl 2):S171–S184.
4. Rontoyanni VG, Sfikakis PP, Kitas GD, Protogerou AD: Marine n-3 fatty acids
for cardiovascular risk reduction and disease control in rheumatoid
arthritis: "kill two birds with one stone"? Curr Pharm Des 2012,
18:1531–1542.
5. O'Brien JS, Sampson EL: Fatty acid and fatty aldehyde composition of the
major brain lipids in normal human gray matter, white matter, and
myelin. J Lipid Res 1965, 6:545–551.
6. Gamoh S, Hashimoto M, Hossain S, Masumura S: Chronic administration of
docosahexaenoic acid improves the performance of radial arm maze
task in aged rats. Clin Exp Pharmacol Physiol 2001, 28:266–270.
7. Gamoh S, Hashimoto M, Sugioka K, Shahdat Hossain M, Hata N, Misawa Y,
Masumura S: Chronic administration of docosahexaenoic acid improves
reference memory-related learning ability in young rats. Neuroscience
1999, 93:237–241.
8. Fontani G, Corradeschi F, Felici A, Alfatti F, Migliorini S, Lodi L: Cognitive
and physiological effects of Omega-3 polyunsaturated fatty acid
supplementation in healthy subjects. Eur J Clin Invest 2005, 35:691–699.
9. Jarrard LE: On the role of the hippocampus in learning and memory in
the rat. Behav Neural Biol 1993, 60:9–26.
10. Milak MS, Parsey RV, Keilp J, Oquendo MA, Malone KM, Mann JJ:
Neuroanatomic correlates of psychopathologic components of major
depressive disorder. Arch Gen Psychiatry 2005, 62:397–408.
11. Videbech P, Ravnkilde B: Hippocampal volume and depression: a meta-
analysis of MRI studies. Am J Psychiatry 2004, 161:1957–1966.
12. Lin PY, Huang SY, Su KP: A meta-analytic review of polyunsaturated fatty
acid compositions in patients with depression. Biol Psychiatry 2010,
68:140–147.
13. Nemets H, Nemets B, Apter A, Bracha Z, Belmaker RH: Omega-3 treatment
of childhood depression: a controlled, double-blind pilot study. Am J
Psychiatry 2006, 163:1098–1100.
14. Carlezon WA Jr, Mague SD, Parow AM, Stoll AL, Cohen BM, Renshaw PF:
Antidepressant-like effects of uridine and omega-3 fatty acids are
potentiated by combined treatment in rats. Biol Psychiatry 2005,
57:343–350.
15. DeMar JC Jr, Ma K, Bell JM, Igarashi M, Greenstein D, Rapoport SI: One
generation of n-3 polyunsaturated fatty acid deprivation increases
depression and aggression test scores in rats. J Lipid Res 2006, 47:172–180.
16. Huang SY, Yang HT, Chiu CC, Pariante CM, Su KP: Omega-3 fatty acids on
the forced-swimming test. J Psychiatr Res 2008, 42:58–63.
17. Park Y, Moon HJ, Kim SH: N-3 polyunsaturated fatty acid consumption
produces neurobiological effects associated with prevention of
depression in rats after the forced swimming test. J Nutr Biochem 2012,
23:924–928.
18. Venna VR, Deplanque D, Allet C, Belarbi K, Hamdane M, Bordet R: PUFA
induce antidepressant-like effects in parallel to structural and
molecular changes in the hippocampus. Psychoneuroendocrinology
2009, 34:199–211.
19. Alme MN, Wibrand K, Dagestad G, Bramham CR: Chronic fluoxetine
treatment induces brain region-specific upregulation of genes
associated with BDNF-induced long-term potentiation. Neural Plast 2007,
2007:26496.
20. Calabrese F, Molteni R, Racagni G, Riva MA: Neuronal plasticity: a link
between stress and mood disorders. Psychoneuroendocrinology 2009,
34(Suppl 1):S208–216.
21. Duman RS, Monteggia LM: A neurotrophic model for stress-related mood
disorders. Biol Psychiatry 2006, 59:1116–1127.
22. Fumagalli F, Caffino L, Racagni G, Riva MA: Repeated stress prevents
cocaine-induced activation of BDNF signaling in rat prefrontal cortex. Eur
Neuropsychopharmacol 2009, 19:402–408.23. Kuipers SD, Bramham CR: Brain-derived neurotrophic factor mechanisms
and function in adult synaptic plasticity: new insights and implications
for therapy. Curr Opin Drug Discov Devel 2006, 9:580–586.
24. Monteggia LM, Luikart B, Barrot M, Theobold D, Malkovska I, Nef S, Parada
LF, Nestler EJ: Brain-derived neurotrophic factor conditional knockouts
show gender differences in depression-related behaviors. Biol Psychiatry
2007, 61:187–197.
25. Rantamaki T, Hendolin P, Kankaanpaa A, Mijatovic J, Piepponen P, Domenici
E, Chao MV, Mannisto PT, Castren E: Pharmacologically diverse
antidepressants rapidly activate brain-derived neurotrophic factor
receptor TrkB and induce phospholipase-Cgamma signaling pathways in
mouse brain. Neuropsychopharmacology 2007, 32:2152–2162.
26. Winther B, Hoem N, Berge K, Reubsaet L: Elucidation of
phosphatidylcholine composition in krill oil extracted from Euphausia
superba. Lipids 2011, 46:25–36.
27. Tou JC, Jaczynski J, Chen YC: Krill for human consumption: nutritional
value and potential health benefits. Nutr Rev 2007, 65:63–77.
28. Nishioka Y, Oyagi A, Tsuruma K, Shimazawa M, Ishibashi T, Hara H: The
antianxiety-like effect of astaxanthin extracted from Paracoccus
carotinifaciens. Biofactors 2011, 37:25–30.
29. Zhang X, Pan L, Wei X, Gao H, Liu J: Impact of astaxanthin-enriched algal
powder of Haematococcus pluvialis on memory improvement in BALB/c
mice. Environ Geochem Health 2007, 29:483–489.
30. Gamoh S: Krill-derived phospholipids rich in n-3 fatty acid improve
spatial memory in adult rats. J Agric Sci 2011, 3:3–12.
31. Bisson JF, Nejdi A, Rozan P, Hidalgo S, Lalonde R, Messaoudi M: Effects of
long-term administration of a cocoa polyphenolic extract (Acticoa
powder) on cognitive performances in aged rats. Br J Nutr 2008,
100:94–101.
32. Rozan P, Deremaux L, Wils D, Nejdi A, Messaoudi M, Saniez MH: Impact of
sugar replacers on cognitive performance and function in rats. Br J Nutr
2008, 100:1004–1010.
33. Messaoudi M, Tricoire A, Jung PH, Desor D, Mocaer E, Lesourd M: Effects of
alnespirone (S 20499) in the depression model (Unavoidable aversive
light stimulus test) in rats. Eur Neuropsychopharmacol 1996, 6:52.
34. Hughes RN, Pither JM: Chronic imipramine effects on exploratory
behavior in rats. Pharmacol Biochem Behav 1987, 27:359–362.
35. Messaoudi M, Bisson JF, Nejdi A, Rozan P, Javelot H: Antidepressant-like
effects of a cocoa polyphenolic extract in Wistar-Unilever rats. Nutr
Neurosci 2008, 11:269–276.
36. Satoh A, Tsuji S, Okada Y, Murakami N, Urami M, Nakagawa K, Ishikura M,
Katagiri M, Koga Y, Shirasawa T: Preliminary Clinical Evaluation of Toxicity
and Efficacy of A New Astaxanthin-rich Haematococcus pluvialis Extract.
J Clin Biochem Nutr 2009, 44:280–284.
37. Shaldubina A, Nemets B, Bersudsky Y: Lack of effect of eicosapentaenoic
acid in the Porsolt forced swimming test model of depression. Acta
Neuropsychiatrica 2002, 14:203–206.
38. Di Marzo V, Griinari M, Carta G, Murru E, Ligresti A, Cordeddu L, Giordano E,
Bisogno T, Collu M, Batetta B, et al: Dietary krill oil increases
docosahexaenoic acid and reduces 2-arachidonoylglycerol but not N-
acylethanolamine levels in the brain of obese Zucker rats. Int Dairy J
2010, 20:231–235.
39. Burri L, Hoem N, Banni S, Berge K: Review. Marine omega-3 phospholipids:
metabolism and biological activities. Int J Mol Sci 2012, 13:15401–15419.
40. Grimstad T, Bjorndal B, Cacabelos D, Aasprong OG, Janssen EA, Omdal R,
Svardal A, Hausken T, Bohov P, Portero-Otin M, et al: Dietary
supplementation of krill oil attenuates inflammation and oxidative stress
in experimental ulcerative colitis in rats. Scand J Gastroenterol 2012,
47:49–58.
41. Alesci S, Martinez PE, Kelkar S, Ilias I, Ronsaville DS, Listwak SJ, Ayala AR,
Licinio J, Gold HK, Kling MA, et al: Major depression is associated with
significant diurnal elevations in plasma interleukin-6 levels, a shift of its
circadian rhythm, and loss of physiological complexity in its secretion:
clinical implications. J Clin Endocrinol Metab 2005, 90:2522–2530.
42. Maes M: The immunoregulatory effects of antidepressants. Hum
Psychopharmacol 2001, 16:95–103.
43. Musselman DL, Lawson DH, Gumnick JF, Manatunga AK, Penna S, Goodkin
RS, Greiner K, Nemeroff CB, Miller AH: Paroxetine for the prevention of
depression induced by high-dose interferon alfa. N Engl J Med 2001,
344:961–966.
Wibrand et al. Lipids in Health and Disease 2013, 12:6 Page 13 of 13
http://www.lipidworld.com/content/12/1/644. Capuron L, Neurauter G, Musselman DL, Lawson DH, Nemeroff CB, Fuchs D,
Miller AH: Interferon-alpha-induced changes in tryptophan metabolism.
relationship to depression and paroxetine treatment. Biol Psychiatry 2003,
54:906–914.
45. Hauser P, Khosla J, Aurora H, Laurin J, Kling MA, Hill J, Gulati M, Thornton AJ,
Schultz RL, Valentine AD, et al: A prospective study of the incidence and
open-label treatment of interferon-induced major depressive disorder in
patients with hepatitis C. Mol Psychiatry 2002, 7:942–947.
46. Genest J: C-reactive protein: risk factor, biomarker and/or therapeutic
target? Can J Cardiol 2010, 26(Suppl A):41A–44A.
47. Kuo HK, Yen CJ, Chang CH, Kuo CK, Chen JH, Sorond F: Relation of C-
reactive protein to stroke, cognitive disorders, and depression in the
general population: systematic review and meta-analysis. Lancet Neurol
2005, 4:371–380.
48. Deutsch L: Evaluation of the effect of Neptune Krill Oil on chronic
inflammation and arthritic symptoms. J Am Coll Nutr 2007, 26:39–48.
49. Park JS, Chyun JH, Kim YK, Line LL, Chew BP: Astaxanthin decreased
oxidative stress and inflammation and enhanced immune response in
humans. Nutr Metab (Lond) 2010, 7:18.
50. Castren E, Voikar V, Rantamaki T: Role of neurotrophic factors in
depression. Curr Opin Pharmacol 2007, 7:18–21.
51. Vines A, Delattre AM, Lima MM, Rodrigues LS, Suchecki D, Machado RB,
Tufik S, Pereira SI, Zanata SM, Ferraz AC: The role of 5-HT(1)A receptors in
fish oil-mediated increased BDNF expression in the rat hippocampus
and cortex: a possible antidepressant mechanism. Neuropharmacology
2012, 62:184–191.
52. Wu A, Ying Z, Gomez-Pinilla F: The salutary effects of DHA dietary
supplementation on cognition, neuroplasticity, and membrane
homeostasis after brain trauma. J Neurotrauma 2011, 28:2113–2122.
53. Delion S, Chalon S, Guilloteau D, Lejeune B, Besnard JC, Durand G:
Age-related changes in phospholipid fatty acid composition and
monoaminergic neurotransmission in the hippocampus of rats fed a
balanced or an n-3 polyunsaturated fatty acid-deficient diet. J Lipid Res
1997, 38:680–689.
54. Ikemoto A, Nitta A, Furukawa S, Ohishi M, Nakamura A, Fujii Y, Okuyama H:
Dietary n-3 fatty acid deficiency decreases nerve growth factor content
in rat hippocampus. Neurosci Lett 2000, 285:99–102.
55. Rao JS, Ertley RN, Lee HJ, DeMar JC Jr, Arnold JT, Rapoport SI, Bazinet RP:
n-3 polyunsaturated fatty acid deprivation in rats decreases frontal
cortex BDNF via a p38 MAPK-dependent mechanism. Mol Psychiatry 2007,
12:36–46.
56. Wibrand K, Messaoudi E, Havik B, Steenslid V, Lovlie R, Steen VM, Bramham
CR: Identification of genes co-upregulated with Arc during BDNF-
induced long-term potentiation in adult rat dentate gyrus in vivo. Eur J
Neurosci 2006, 23:1501–1511.
57. Bramham CR, Alme MN, Bittins M, Kuipers SD, Nair RR, Pai B, Panja D,
Schubert M, Soule J, Tiron A, Wibrand K: The Arc of synaptic memory. Exp
Brain Res 2010, 200:125–140.
58. Shepherd JD, Bear MF: New views of Arc, a master regulator of synaptic
plasticity. Nat Neurosci 2011, 14:279–284.
59. Gil-Bea FJ, Solas M, Mateos L, Winblad B, Ramirez MJ, Cedazo-Minguez A:
Cholinergic hypofunction impairs memory acquisition possibly through
hippocampal Arc and BDNF downregulation. Hippocampus 2011,
21:999–1009.
60. Soule J, Alme M, Myrum C, Schubert M, Kanhema T, Bramham CR:
Balancing Arc synthesis, mRNA decay, and proteasomal degradation:
maximal protein expression triggered by rapid eye movement sleep-like
bursts of muscarinic cholinergic receptor stimulation. J Biol Chem 2012,
287:22354–22366.
61. Teber I, Kohling R, Speckmann EJ, Barnekow A, Kremerskothen J: Muscarinic
acetylcholine receptor stimulation induces expression of the activity-
regulated cytoskeleton-associated gene (ARC). Brain Res Mol Brain Res
2004, 121:131–136.
62. Blusztajn JK, Liscovitch M, Richardson UI: Synthesis of acetylcholine from
choline derived from phosphatidylcholine in a human neuronal cell line.
Proc Natl Acad Sci USA 1987, 84:5474–5477.
63. Minami M, Kimura S, Endo T, Hamaue N, Hirafuji M, Togashi H, Matsumoto
M, Yoshioka M, Saito H, Watanabe S, et al: Dietary docosahexaenoic acid
increases cerebral acetylcholine levels and improves passive avoidance
performance in stroke-prone spontaneously hypertensive rats. Pharmacol
Biochem Behav 1997, 58:1123–1129.64. Messaoudi M, Lalonde R, Nejdi A, Bisson JF, Rozan P, Javelot H, Schroeder H:
The effects of Garum Armoricum on elevated-plus maze and
conditioned light extinction tests in rats. Curr Topics Nutraceutical Res
2008, 6:41–46.
65. Porsolt RD, Anton G, Blavet N, Jalfre M: Behavioural despair in rats: a new
model sensitive to antidepressant treatments. Eur J Pharmacol 1978,
47:379–391.
66. Porsolt RD, Le Pichon M, Jalfre M: Depression: a new animal model
sensitive to antidepressant treatments. Nature 1977, 266:730–732.
67. Butterweck V, Nishibe S, Sasaki T, Uchida M: Antidepressant effects of
apocynum venetum leaves in a forced swimming test. Biol Pharm Bull
2001, 24:848–851.
68. Andersen CL, Jensen JL, Orntoft TF: Normalization of real-time
quantitative reverse transcription-PCR data: a model-based variance
estimation approach to identify genes suited for normalization, applied
to bladder and colon cancer data sets. Cancer Res 2004, 64:5245–5250.
doi:10.1186/1476-511X-12-6
Cite this article as: Wibrand et al.: Enhanced cognitive function and
antidepressant-like effects after krill oil supplementation in rats. Lipids in
Health and Disease 2013 12:6.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
